Trevi Therapeutics, Inc.

Single-asset clinical-stage company developing Haduvio (oral nalbuphine ER), a kappa-opioid agonist / mu-opioid antagonist, for chronic cough indications with limited treatment options. Lead programs are the Phase 3 RIVER trial in chronic cough associated with idiopathic pulmonary fibrosis and the Phase 2b CORAL trial in refractory chronic cough.